4.27
0.12 (2.89%)
| Previous Close | 4.15 |
| Open | 4.16 |
| Volume | 6,111,168 |
| Avg. Volume (3M) | 9,034,467 |
| Market Cap | 2,573,938,944 |
| Price / Sales | 1.85 |
| Price / Book | 8.20 |
| 52 Weeks Range | |
| Earnings Date | 31 Oct 2024 - 4 Nov 2024 |
| Operating Margin (TTM) | -7,860.88% |
| Diluted EPS (TTM) | -0.350 |
| Quarterly Revenue Growth (YOY) | 2,941.40% |
| Total Debt/Equity (MRQ) | 28.38% |
| Current Ratio (MRQ) | 3.61 |
| Operating Cash Flow (TTM) | -207.51 M |
| Levered Free Cash Flow (TTM) | -126.95 M |
| Return on Assets (TTM) | -32.87% |
| Return on Equity (TTM) | -72.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Geron Corporation | Bearish | Bullish |
Stockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.09% |
| % Held by Institutions | 77.95% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Jun 2024 | 23,915,480 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (Leerink Partners, 63.93%) | Buy |
| Median | 6.00 (40.52%) | |
| Low | 6.00 (Scotiabank, 40.52%) | Buy |
| 6.00 (Needham, 40.52%) | Buy | |
| Average | 6.33 (48.24%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 4.43 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 16 Oct 2024 | 6.00 (40.52%) | Buy | 4.17 |
| Leerink Partners | 09 Sep 2024 | 7.00 (63.93%) | Buy | 4.41 |
| Needham | 09 Aug 2024 | 6.00 (40.52%) | Buy | 4.70 |
| 26 Jul 2024 | 6.00 (40.52%) | Buy | 4.66 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |